Imatinib mesylate inhibits cell growth of malignant peripheral nerve sheath tumors in vitro and in vivo through suppression of PDGFR-beta

Conclusions:
The results suggest that imatinib mesylate may be useful in the treatment of MPNST patients and in vitro studies may help select cells that are sensitive to imatinib mesylate in vivo.

Source: BMC Cancer - May 4, 2013 Category: Cancer & Oncology Authors: Jun OhishiMikiko AokiKazuki NabeshimaJunji SuzumiyaTamotsu TakeuchiAkira OgoseMichiyuki HakozakiYuichi YamashitaHiroshi Iwasaki Source Type: research